Functional analysis of CYP2D6.31 variant:: Homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution

被引:23
作者
Allorge, D
Bréant, D
Harlow, J
Chowdry, J
Lo-Guidice, JM
Chevalier, D
Cauffiez, C
Lhermitte, M
Blaney, FE
Tucker, GRT
Broly, F
Ellis, SW
机构
[1] Univ Sheffield, Div Clin Sci, Unit Mol & Clin Pharmaol, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[2] Fac Med Lille, EA 2679, F-59045 Lille, France
[3] GlaxoSmithKline Res & Dev, Computat Analyt & Struct Sci, Harlow, Essex, England
关键词
CYP2D6.31; diminished activity; reductase interaction; homology modeling;
D O I
10.1002/prot.20399
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 2D6 (CYP2D6) is an important human drug-metabolizing enzyme that exhibits a marked genetic polymorphism. Numerous CYP2D6 alleles have been characterized at a functional level, although the consequences for expression and/or catalytic activity of a substantial number of rare variants remain to be investigated. One such allele, CTP2D6*31, is characterized by mutations encoding three amino acid substitutions: Arg296Cys, Arg440His and Ser486Thr. The identification of this allele, in an individual with an apparent in vivo poor metabolizer phenotype prompted us to analyze the functional consequence of these substitutions on enzyme activity using yeast as a heterologous expression system. We demonstrated that the Arg440His substitution, alone or in combination with Arg296Cys and/or Ser486Thr, altered the respective kinetic parameters [K-m (mu M) and k(cat) (min(-1))] of debrisoquine 4-hydroxylation (wild-type, 25; 0.92; variants, 43-68; 0.05-0.11) and dextromethorphan O-demethylation (wild-type, 1; 4.72; variants, 12-23; 0.64-1.43), such that their specificity constants (k(cat)/K-m) were decreased by more than 95% compared to those observed with the wild-type enzyme. The rates of oxidation of rac-metoprolol. at single substrate concentrations of 40 and 400 mu M were also markedly decreased by approximately 90% with each CYP2D6 variant containing the Arg440His substitution. These in vitro data confirm that the CYP2D6*31 allele encodes an enzyme with a severely impaired but residual catalytic activity and, furthermore, that the Arg440His exchange alone is the inactivating mutation. A homology model of CYP2D6 based on the crystal structure of rabbit CYP2C5 locates Arg440 on the proximal surface of the protein. Docking the structure of the FAIN domain of human cytochrome P450 reductase to the CYP2D6 model suggests that Arg440 is a key member of a cluster of basic amino acid residues important for reductase binding. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 43 条
[1]   Gapped BLAST and PSI-BLAST: a new generation of protein database search programs [J].
Altschul, SF ;
Madden, TL ;
Schaffer, AA ;
Zhang, JH ;
Zhang, Z ;
Miller, W ;
Lipman, DJ .
NUCLEIC ACIDS RESEARCH, 1997, 25 (17) :3389-3402
[2]   The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant -: Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations [J].
Bapiro, TE ;
Hasler, JA ;
Ridderström, M ;
Masimirembwa, CM .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (09) :1387-1398
[3]   Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists [J].
Blaney, FE ;
Raveglia, LF ;
Artico, M ;
Cavagnera, S ;
Dartois, C ;
Farina, C ;
Grugni, M ;
Gagliardi, S ;
Luttmann, MA ;
Martinelli, M ;
Nadler, GMMG ;
Parini, C ;
Petrillo, P ;
Sarau, HM ;
Scheideler, MA ;
Hay, DWP ;
Giardina, GAM .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (11) :1675-1689
[4]   DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE [J].
BROLY, F ;
MEYER, UA .
PHARMACOGENETICS, 1993, 3 (03) :123-130
[5]   SIMULTANEOUS DETERMINATION OF DEXTROMETHORPHAN AND 3 METABOLITES IN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH APPLICATION TO THEIR DISPOSITION IN MAN [J].
CHEN, ZR ;
SOMOGYI, AA ;
BOCHNER, F .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :97-104
[6]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[7]   Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (09) :1515-1524
[8]   Theoretical investigation of substrate specificity for cytochromes p450 IA2, p450 IID6 and p450 IIIA4 [J].
De Rienzo, F ;
Fanelli, F ;
Menziani, MC ;
De Benedetti, PG .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2000, 14 (01) :93-116
[9]   BACKBONE-DEPENDENT ROTAMER LIBRARY FOR PROTEINS - APPLICATION TO SIDE-CHAIN PREDICTION [J].
DUNBRACK, RL ;
KARPLUS, M .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 230 (02) :543-574
[10]   Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol [J].
Ellis, SW ;
Rowland, K ;
Ackland, MJ ;
Rekka, E ;
Simula, AP ;
Lennard, MS ;
Wolf, CR ;
Tucker, GT .
BIOCHEMICAL JOURNAL, 1996, 316 :647-654